Mediven Receives CE Mark for Molecular, Rapid Immunoassay Tests

Jun 08, 2016

|

NEW YORK (GenomeWeb) – Medical Innovation Ventures (Mediven) has received the CE-IVD mark for molecular and rapid tests that facilitate diagnosis for fecal occult blood, pregnancy, dengue, and tuberculosis.

One of the rapid tests, the ProDetect FOB Rapid Test, is a direct binding immunoassay for rapidly and qualitatively detecting the presence of human occult blood in feces. The other rapid pregnancy tests detect the presence of hCG in urine during the early stages of pregnancy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Commission's First Meeting

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

More Scrutiny

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Web of Neutrophil DNA

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

Science Explores Method to Infer Genotype-by-Environment Interactions

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.

Menu